New advances in Traditional Chinese Medicine interventions for epilepsy: where are we and what do we know?

被引:0
|
作者
Sun, Minjuan [1 ]
Qiu, Xiaoyun [1 ]
Yuan, Zhijian [1 ]
Xu, Cenglin [1 ]
Chen, Zhong [1 ]
机构
[1] Zhejiang Chinese Med Univ, Sch Clin Med 5, Huzhou Cent Hosp, Coll Pharmaceut Sci,Key Lab Neuropharmacol & Trans, Hangzhou, Zhejiang, Peoples R China
来源
CHINESE MEDICINE | 2025年 / 20卷 / 01期
基金
中国国家自然科学基金;
关键词
Epilepsy; Traditional Chinese Medicine; Herbal medicine; Prescription; Acupuncture; Epileptic comorbidities; STATUS EPILEPTICUS; TANSHINONE IIA; ANTICONVULSANT ACTIVITY; UNCARIA-RHYNCHOPHYLLA; COGNITIVE IMPAIRMENT; CURCUMA-LONGA; MODEL; SEIZURES; HIPPOCAMPAL; DEPRESSION;
D O I
10.1186/s13020-025-01088-z
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Epilepsy, one of the most common neurological diseases, affects more than 70 million people worldwide. Anti-seizure drugs targeting membrane ion channels or GABAergic neurotransmission are the first choices for controlling seizures, whereas the high incidence of pharmacoresistance and adverse effects largely restrict the availability of current anti-seizure drugs (ASDs). Traditional Chinese Medicine (TCM) has shown historical evidence-based therapeutic effects for neurological diseases including epilepsy. But until the late 1990s, great efforts in both clinical and experimental fields advanced TCM interventions for epilepsy from evidence-based practices to more systematic neuropharmacological significance, and show new lights on preferable management of epilepsy in the last decade. This review summarized the advances of applying TCM interventions (ranging from herbal medicines and their active ingredients to other strategies such as acupuncture) for epilepsy, followed by associated mechanism theories. The therapeutic potential of TCM interventions for epilepsy as well as its comorbidities turns from somehow debatable to hopeful. Finally, some prospects and directions were proposed to drive further clinical translational research. The future directions of TCM should aim at not only deriving specific anti-epileptic molecules but also illustrating more precise mechanisms with the assistance of advanced multifaceted experimental tools.
引用
收藏
页数:21
相关论文
共 50 条
  • [1] Cannabinoids for epilepsy: What do we know and where do we go?
    Brodie, Martin J.
    Ben-Menachem, Elinor
    EPILEPSIA, 2018, 59 (02) : 291 - 296
  • [2] What we know, what we do not know, and where are we heading? Efficacy and acceptability of psychological interventions for depression
    Solomonov, N.
    Barber, J. P.
    EPIDEMIOLOGY AND PSYCHIATRIC SCIENCES, 2016, 25 (04) : 301 - 308
  • [3] Microbiome in Multiple Sclerosis: Where Are We, What We Know and Do Not Know
    Boziki, Marina Kleopatra
    Kesidou, Evangelia
    Theotokis, Paschalis
    Mentis, Alexios-Fotios A.
    Karafoulidou, Eleni
    Melnikov, Mikhail
    Sviridova, Anastasia
    Rogovski, Vladimir
    Boyko, Alexey
    Grigoriadis, Nikolaos
    BRAIN SCIENCES, 2020, 10 (04)
  • [4] Racial/ethnic disparities in the treatment of epilepsy: What do we know? What do we need to know?
    Szaflarski, Magdalena
    Szaflarski, Jerzy P.
    Privitera, Michael D.
    Ficker, David M.
    Horner, Ronnie D.
    EPILEPSY & BEHAVIOR, 2006, 9 (02) : 243 - 264
  • [5] MENSTRUALLY RELATED DISORDERS - WHAT WE DO KNOW, WHAT WE ONLY BELIEVE THAT WE KNOW, AND WHAT WE KNOW THAT WE DO NOT KNOW
    HALBREICH, U
    CRITICAL REVIEWS IN NEUROBIOLOGY, 1995, 9 (2-3): : 163 - 175
  • [6] Sleep deprivation in Depression: What do we know, where do we go?
    Wirz-Justice, A
    Van den Hoofdakker, RH
    BIOLOGICAL PSYCHIATRY, 1999, 46 (04) : 445 - 453
  • [7] Psychological flexibility: What we know, what we do not know, and what we think we know
    Doorley, James D.
    Goodman, Fallon R.
    Kelso, Kerry C.
    Kashdan, Todd B.
    SOCIAL AND PERSONALITY PSYCHOLOGY COMPASS, 2020, 14 (12) : 1 - 11
  • [8] Fenfluramine repurposing from weight loss to epilepsy: What we do and do not know
    Odi, Reem
    Invernizzi, Roberto William
    Gallily, Tamar
    Bialer, Meir
    Perucca, Emilio
    PHARMACOLOGY & THERAPEUTICS, 2021, 226
  • [9] ECONOMIC NETWORKS: WHAT DO WE KNOW AND WHAT DO WE NEED TO KNOW?
    Schweitzer, Frank
    Fagiolo, Giorgio
    Sornette, Didier
    Vega-Redondo, Fernando
    White, Douglas R.
    ADVANCES IN COMPLEX SYSTEMS, 2009, 12 (4-5): : 407 - 422
  • [10] Neuroproteomics in Epilepsy: What Do We Know so Far?
    do Canto, Amanda M.
    Donatti, Amanda
    Geraldis, Jaqueline C.
    Godoi, Alexandre B.
    da Rosa, Douglas C.
    Lopes-Cendes, Iscia
    FRONTIERS IN MOLECULAR NEUROSCIENCE, 2021, 13